Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 5/20 | 0.51 |
| ▸ | FAAH | O00519 | 3/20 | 0.51 |
| ▸ | CNR1 | P21554 | 2/20 | 0.49 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.49 |
| ▸ | CNR2 | P34972 | 1/20 | 0.49 |
| ▸ | SOAT2 | O75908 | 1/20 | 0.47 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.47 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6348306 | 1.00 | EPHX2 (0.51) | EPHX2FAAHCNR1LPAR1CNR2 | |
| SCHEMBL6346335 | 0.85 | EPHX2 (0.56) | EPHX2FAAHCNR1LPAR1CNR2 | |
| SCHEMBL6346341 | 0.85 | EPHX2 (0.56) | EPHX2FAAHCNR1LPAR1CNR2 | |
| SCHEMBL10940345 | 0.85 | ASAH1 (0.51) | EPHX2FAAHCNR1LPAR1CNR2 | |
| SCHEMBL6338180 | 0.84 | LPAR1 (0.54) | EPHX2FAAHCNR1LPAR1CNR2 | |
| SCHEMBL6338178 | 0.84 | LPAR1 (0.54) | EPHX2FAAHCNR1LPAR1CNR2 | |
| SCHEMBL7589241 | 0.82 | ASAH1 (0.52) | EPHX2FAAHLPAR1ASAH1MEN1 | |
| SCHEMBL14032153 | 0.81 | PLA2G4A (0.48) | EPHX2FAAHSOAT2SOAT1MEN1 | |
| SCHEMBL14032313 | 0.81 | PLA2G4A (0.48) | EPHX2FAAHSOAT2SOAT1MEN1 | |
| SCHEMBL17586542 | 0.81 | PLA2G4A (0.48) | EPHX2FAAHSOAT2SOAT1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6911553-B1 | Osteoblast-specific mitogens and drugs containing such compounds | ROCHE DIAGNOSTICS GMBH (DE) | 2005-06-28 | — | — | US | disclosed |
| US-20050014723-A1 | Osteoblast-specific mitogens and drugs containing such compounds | ESSWEIN ANGELIKA (DE) | 2005-01-20 | — | — | US | disclosed |
| US-6197759-B1 | ADMINISTERING LYSOPHOSPHATIDYLIC ACID DERIVATIVE | ROCHE DIAGNOSTICS GMBH (DE) | 2001-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014723-A1 | Osteoblast-specific mitogens and drugs containing such compounds | LPAR1, LPAR2, LPAR4 | EPHX2 84/4885FAAH 531/4885CNR1 408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.